eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2020-09-25 13 3 1543 1548 10.13005/bpj/2028 35022 article Tiffani Shavira Arnetha 1 Bethy Suryawathy Hernowo 2 Melia Juwita Adha 3 Andri Rezano 4 Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia, 45363. Department of Anatomic Pathology, Faculty of Medicine, Universitas Padjadjaran/ Hasan Sadikin General Hospital, Bandung, Indonesia, 40161. Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung, Indonesia, 40161. Department of Biomedical Sciences, Division of Cell Biology, Faculty of Medicine Universitas Padjadjaran, Sumedang, Indonesia, 45363. Breast cancer is a complex disease that encompasses various kinds of molecular subtypes with heterogeneous characteristics for each type. More information is needed to guide treatment decisions. This study aims to estimate the prevalence of breast cancer subtypes and to determine the relationship between molecular subtypes and overall survival (OS) for breast cancer patients. Retrospective analysis was conducted to examine 468 breast cancer cases diagnosed from January 2011 to September 2011 and had a radical mastectomy at Hasan Sadikin General Hospital Bandung. Age, clinical staging, and molecular subtypes were analyzed on 63 patients from medical records. The patient’s conditions were followed up within five years. Molecular subtypes of breast cancer were divided into luminal A, luminal B, HER2, and triple-negative based on receptor characteristics. Patient OS was measured by Kaplan-Meier analysis and the Log-rank test to estimate outcome differences among subtypes. Luminal A (46%) subtypes were the most prevalent, followed by HER2 (27%), triple-negative (14,3%), and luminal B (12,7%). These tumors were commonly found in women above 40 years old. OS analysis showed a significant difference between subtypes. Luminal A and triple-negative tumors were associated with good and worse prognosis respectively. In conclusion, information on molecular classification in breast cancer patients was necessary for estimating treatment implications and breast cancer patient prognosis. https://biomedpharmajournal.org/vol13no3/relationship-between-molcular-subtypes-and-overall-survival-of-breast-cancer-in-bandung/ Breast Cancer Molecular Classification Therapeutic Response Receptor Characteristics Patient Outcome.